Networking, like science, requires time, effort and confidence. However, networking, unlike science, rarely earns a place in the curriculum. Despite the importance it plays in the establishment of
Australia’s regenerative medicine research output is world-renowned, as evidenced by not only the volume of publications in high-impact journals but also the number of emerging biotech companies. As
In 2008, mesenchymal stem cells were not gracing the front page of prestigious academic journals as they do today. Yet the founders of Regeneus knew differently. A company
As stem cell therapies move through clinical trials and get closer to the clinic, they are giving rise to new challenges, primarily around costs and the likelihood of
From Biotech Daily, Friday February 9, 2018 By Tim Boreham ASX code: CYP Share price: 82 cents; Shares on issue: 90,057,248 Market cap: $73.8 million Chief executive officer: Dr
A successful scientist is also an entrepreneur. For emerging regenerative medicine (RM) companies and researchers such as Rebecca Lim – this is no revelation. Understanding the importance of
RM in a nutshell It is well known within regenerative medicine industry circles that the Australian sector shows clear potential and successful academic research. However, when it comes
A leading Australian stem and regenerative medicine company, Cynata Therapeutics was established with the objective of developing therapeutic products using the Cymerus™ technology. With innovative research, translation and
The long-term sustainability of RM is by no means certain and there has been a palpable lack of business and commercial consideration within emerging RM industries. Without an
